Annual Cash & Cash Equivalents
$70.64 M
+$5.14 M+7.85%
31 December 2023
Summary:
Leap Therapeutics annual cash & cash equivalents is currently $70.64 million, with the most recent change of +$5.14 million (+7.85%) on 31 December 2023. During the last 3 years, it has risen by +$18.57 million (+35.67%). LPTX annual cash & cash equivalents is now -38.53% below its all-time high of $114.92 million, reached on 31 December 2021.LPTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$62.82 M
-$15.66 M-19.95%
30 September 2024
Summary:
Leap Therapeutics quarterly cash and cash equivalents is currently $62.82 million, with the most recent change of -$15.66 million (-19.95%) on 30 September 2024. Over the past year, it has dropped by -$17.92 million (-22.19%). LPTX quarterly cash and cash equivalents is now -49.65% below its all-time high of $124.77 million, reached on 30 September 2021.LPTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LPTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.8% | -22.2% |
| 3 y3 years | +35.7% | -49.6% |
| 5 y5 years | +333.8% | +524.6% |
LPTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -38.5% | +35.7% | -49.6% | +14.4% |
| 5 y | 5 years | -38.5% | +1715.5% | -49.6% | +1514.6% |
| alltime | all time | -38.5% | >+9999.0% | -49.6% | >+9999.0% |
Leap Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $62.82 M(-19.9%) |
| June 2024 | - | $78.48 M(+42.9%) |
| Mar 2024 | - | $54.92 M(-22.3%) |
| Dec 2023 | $70.64 M(+7.9%) | $70.64 M(-12.5%) |
| Sept 2023 | - | $80.74 M(-11.7%) |
| June 2023 | - | $91.42 M(-10.4%) |
| Mar 2023 | - | $102.04 M(+55.8%) |
| Dec 2022 | $65.50 M(-43.0%) | $65.50 M(-16.4%) |
| Sept 2022 | - | $78.31 M(-13.8%) |
| June 2022 | - | $90.88 M(-12.0%) |
| Mar 2022 | - | $103.22 M(-10.2%) |
| Dec 2021 | $114.92 M(+120.7%) | $114.92 M(-7.9%) |
| Sept 2021 | - | $124.77 M(+249.2%) |
| June 2021 | - | $35.73 M(-17.8%) |
| Mar 2021 | - | $43.49 M(-16.5%) |
| Dec 2020 | $52.07 M(+1238.2%) | $52.07 M(-10.2%) |
| Sept 2020 | - | $57.98 M(-10.7%) |
| June 2020 | - | $64.89 M(+154.8%) |
| Mar 2020 | - | $25.46 M(+554.5%) |
| Dec 2019 | $3.89 M | $3.89 M(-61.3%) |
| Sept 2019 | - | $10.06 M(-36.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2019 | - | $15.75 M(-27.5%) |
| Mar 2019 | - | $21.71 M(+33.3%) |
| Dec 2018 | $16.28 M(-36.7%) | $16.28 M(-30.0%) |
| Sept 2018 | - | $23.25 M(-23.7%) |
| June 2018 | - | $30.48 M(-13.8%) |
| Mar 2018 | - | $35.38 M(+37.5%) |
| Dec 2017 | $25.74 M(+3145.5%) | $25.74 M(+81.2%) |
| Sept 2017 | - | $14.20 M(-17.3%) |
| June 2017 | - | $17.17 M(-27.9%) |
| Mar 2017 | - | $23.80 M(+2901.3%) |
| Dec 2016 | $793.00 K(+95.8%) | $793.00 K(-96.9%) |
| June 2016 | - | $25.46 M(+6187.2%) |
| Dec 2015 | $405.00 K(-96.3%) | $405.00 K(-96.5%) |
| Sept 2015 | - | $11.52 M(+20.1%) |
| June 2015 | - | $9.59 M(-20.2%) |
| Mar 2015 | - | $12.02 M(+10.6%) |
| Dec 2014 | $10.87 M(-42.8%) | $10.87 M(-76.3%) |
| Sept 2014 | - | $45.78 M(+309.1%) |
| June 2014 | - | $11.19 M(-30.0%) |
| Mar 2014 | - | $15.98 M(-15.9%) |
| Dec 2013 | $19.00 M(+24.0%) | $19.00 M |
| Dec 2012 | $15.32 M | - |
FAQ
- What is Leap Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Leap Therapeutics?
- What is Leap Therapeutics annual cash & cash equivalents year-on-year change?
- What is Leap Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Leap Therapeutics?
- What is Leap Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Leap Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of LPTX is $70.64 M
What is the all time high annual cash & cash equivalents for Leap Therapeutics?
Leap Therapeutics all-time high annual cash & cash equivalents is $114.92 M
What is Leap Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, LPTX annual cash & cash equivalents has changed by +$5.14 M (+7.85%)
What is Leap Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LPTX is $62.82 M
What is the all time high quarterly cash and cash equivalents for Leap Therapeutics?
Leap Therapeutics all-time high quarterly cash and cash equivalents is $124.77 M
What is Leap Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, LPTX quarterly cash and cash equivalents has changed by -$17.92 M (-22.19%)